CSIMarket
 


Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 

Rocket Pharmaceuticals Inc 's Tangible Leverage Ratio

RCKT's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




RCKT Tangible Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity Change -26.02 % -22.18 % -13.89 % 100.88 % 92.97 %
Y / Y Total Liabilities Change 12.04 % -3.41 % -55.92 % -54.84 % -48.48 %
Tangible Leverage Ratio MRQ 0.15 0.12 0.11 0.1 0.1
Overall Ranking # # # # #
Seq. Tangible Equity Change -5.71 % -7.74 % -8.75 % -6.8 % -0.82 %
Seq. Total Liabilities Change 13.13 % 3.82 % 0.55 % -5.13 % -2.48 %



Tangible Leverage Ratio third quarter 2022 Comment
Due to net new borrowings of 13.13%, Tangible Leverage Ratio detoriated to 0.15, above company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry Rocket Pharmaceuticals Inc achieved lowest Tangible Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Tangible Leverage Ratio?
What is RCKT Market Share?
Tangible Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Tangible Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Rocket Pharmaceuticals Inc 's Tangible Equity $ 336 Millions Visit RCKT's Balance sheet
Rocket Pharmaceuticals Inc 's Total Liabilities $ 50 Millions Visit RCKT's Balance sheet
Source of RCKT's Sales Visit RCKT's Sales by Geography


Cumulative Rocket Pharmaceuticals Inc 's Tangible Leverage Ratio

RCKT's Tangible Leverage Ratio for the trailling 12 Months

RCKT Tangible Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity TTM Growth -26.02 % -22.18 % -13.89 % 100.88 % 92.97 %
Y / Y Total Liabilities TTM Growth 12.04 % -3.41 % -55.92 % -54.84 % -48.48 %
Tangible Leverage Ratio TTM 0.12 0.11 0.1 0.13 0.18
Total Ranking TTM # 237 # 265 # 256 # 338 # 409
Seq. Tangible Equity TTM Growth -5.71 % -7.74 % -8.75 % -6.8 % -0.82 %
Seq. Total Liabilities TTM Growth 13.13 % 3.82 % 0.55 % -5.13 % -2.48 %


TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Due to net new borrowings of 13.13%, Tangible Leverage Ratio improved to 0.12, below Rocket Pharmaceuticals Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 91 other companies have achieved lower Tangible Leverage Ratio than Rocket Pharmaceuticals Inc . While total ranking remained unchanged compare to previous quarter at no. 237.

Explain Tangible Leverage Ratio?
What is RCKT Market Share?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 140
Within the Market # 237


TTM Tangible Leverage Ratio Statistics
High Average Low
0.31 0.22 0.09
(Jun 30 2019)   (Mar 31 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Tangible Equity
Cyclacel Pharmaceuticals Inc   0.41 $ 8.954  Millions$ 22.067  Millions
Calithera Biosciences Inc   0.41 $ 10.695  Millions$ 26.388  Millions
Bicycle Therapeutics Plc  0.40 $ 116.677  Millions$ 289.474  Millions
Dermata Therapeutics Inc   0.40 $ 3.009  Millions$ 7.471  Millions
Arbutus Biopharma Corp  0.40 $ 58.284  Millions$ 145.517  Millions
Maia Biotechnology Inc   0.40 $ 4.913  Millions$ 12.326  Millions
Rhythm Pharmaceuticals inc   0.40 $ 108.419  Millions$ 273.098  Millions
Merus N v   0.39 $ 116.213  Millions$ 296.888  Millions
Moonlake Immunotherapeutics  0.39 $ 32.247  Millions$ 82.568  Millions
Liquidia Corporation  0.39 $ 33.765  Millions$ 87.319  Millions
Vistagen Therapeutics Inc   0.37 $ 11.097  Millions$ 29.605  Millions
Kintara Therapeutics Inc   0.37 $ 3.592  Millions$ 9.618  Millions
Prothena Corporation Public Limited Company  0.37 $ 149.792  Millions$ 404.648  Millions
Inmed Pharmaceuticals Inc   0.37 $ 3.282  Millions$ 8.940  Millions
Aeglea Biotherapeutics Inc   0.36 $ 24.011  Millions$ 67.555  Millions
Procyon Corp  0.35 $ 0.927  Millions$ 2.643  Millions
Nurix Therapeutics Inc.  0.34 $ 116.793  Millions$ 342.545  Millions
Provention Bio Inc   0.34 $ 49.144  Millions$ 144.769  Millions
Y mabs Therapeutics inc   0.34 $ 36.017  Millions$ 106.368  Millions
Repare Therapeutics Inc   0.34 $ 103.382  Millions$ 305.776  Millions
Vaccinex Inc   0.34 $ 2.131  Millions$ 6.318  Millions
Ampio Pharmaceuticals inc   0.34 $ 4.657  Millions$ 13.849  Millions
Vyne Therapeutics Inc   0.34 $ 13.470  Millions$ 40.069  Millions
Thorne Healthtech Inc   0.33 $ 32.963  Millions$ 99.774  Millions
Vertex Pharmaceuticals Inc  0.32 $ 3,676.800  Millions$ 11,350.800  Millions
Magenta Therapeutics Inc   0.32 $ 40.098  Millions$ 124.025  Millions
Gt Biopharma Inc   0.32 $ 5.117  Millions$ 15.954  Millions
Werewolf Therapeutics Inc   0.32 $ 41.477  Millions$ 130.947  Millions
89bio Inc   0.31 $ 48.005  Millions$ 152.575  Millions
Generation Bio Co   0.30 $ 94.050  Millions$ 308.749  Millions

Date modified: 2022-11-06T22:01:58+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PKI's Profile

Stock Price

PKI's Financials

Business Description

Fundamentals

Charts & Quotes

PKI's News

Suppliers

PKI's Competitors

Customers & Markets

Economic Indicators

PKI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071